Study quantifies risk of blood clots in patients with COVID-19; Biden administration aims to reverse restrictions on fetal tissue research; Michigan hospitals struggle to care for COVID-19 cases.
Amid a continued pause of Johnson & Johnson’s COVID-19 vaccine in the United States, a new study suggests risks of experiencing dangerous blood clots in the brain are much higher among individuals who contract COVID-19 than in those who receive vaccines developed by AstraZeneca, Pfizer, or Moderna, CBS News reports. The study, which has not yet been peer reviewed, found the risk of experiencing a blood clot in the brain was 95 times greater among those who contract COVID-19 compared with the general population. Researchers hope the findings will boost confidence in all the major vaccines currently available in the Western world.
The Biden administration is preparing to announce it will change Trump-era restrictions on federal funding on research that uses fetal tissue, The Washington Post reports. The reversal allows for a potential resumption of studies into COVID-19 treatments, HIV and other diseases. First disclosed by HHS secretary Xavier Becerra to lawmakers, he did not provide details of the policy shift. Under the rules imposed by former President Trump, the NIH was prohibited from providing money for fetal tissue research by government-employed scientists. Fetal tissue has been used in research since the 1950s, when Swedish scientists developed a polio vaccine using fetal cells.
At Michigan’s largest hospital system in suburban Detroit, staff and faculty are facing a wave of COVID-19 cases, forcing some to provide outdoor evaluations as patients show up for care, according to the Associated Press. The health system, Beaumont Health, has 8 hospitals in southeastern Michigan and is currently treating more than 800 patients with COVID-19—an increase from about 500 2 weeks ago. Statewide, the number of patients with confirmed COVID-19 was near 4000, with 4 hospitals reporting they were at 100% capacity this week. The surge comes as the state continues to report the nation’s highest 7-day case rate at 551 per 100,000.
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
American Advocacy and Action for Minority Health in 2025
April 4th 2025Accessing equitable health care is an ongoing struggle in the US for minority communities due to historical pretexts with new setbacks surfacing as recent administrative changes emerge, highlighting the urgent need for continued advocacy during National Minority Health Month.
Read More